Results 11 to 20 of about 188,223 (344)
Rituximab Iodination Procedure for Radioiodinated Rituximab (131I-Rituximab) Preparation [PDF]
Majalah Kedokteran Bandung, 2019 Rituximab is a chimeric monoclonal antibody which has specific for CD20 antigen expressed by pre-B and mature B-cells. Radiolabelled Rituximab, 131I-Rituximab, has been sucessfully used for treatment of B-Cell NHL.
Martalena Ramli +4 more
doaj +3 more sources
Rituximab in Membranous Nephropathy [PDF]
Kidney International Reports, 2021 Membranous nephropathy (MN) is the most common cause of primary nephrotic syndrome among adults. The identification of phospholipase A2 receptor (PLA2R) as target antigen in most patients changed the management of MN dramatically, and provided a rationale for B-cell depleting agents such as rituximab. The efficacy of rituximab in inducing remission has
Philipp Gauckler +77 more
openaire +13 more sources
Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. [PDF]
, 2004 BACKGROUND: An open-label study indicated that selective depletion of B cells with the use of rituximab led to sustained clinical improvements for patients with rheumatoid arthritis. To confirm these observations, we conducted a randomized, double-blind,
Close, DR +7 more
core +1 more source
BMC Rheumatology, 2022 Background This pilot study’s primary aim was to determine if oligoclonal B cell expansion in children with Juvenile Dermatomyositis (JDM) predicts response to Rituximab therapy.
Elisa Ochfeld +6 more
doaj +1 more source
Experience with the use of Rituximab for the treatment of rheumatoid arthritis in a tertiary Hospital in Spain: RITAR study [PDF]
, 2019 There is evidence supporting that there are no relevant clinical differences between dosing rituximab 1000 mg or 2000 mg per cycle in rheumatoid arthritis (RA) patients in clinical trials, and low-dose cycles seem to have a better safety profile ...
Alvaro García, José M. +11 more
core +2 more sources
Indian Pediatrics, 2011 Rituximab is a chimeric mouse-human monoclonal antibody against the CD 20 antigen on the surface of B lymphocytes. It binds to CD20 and causes B cell death by antibody dependant cell-mediated cytotoxicity, complement mediated cytotoxicity and apoptosis. It leads to rapid and sustained depletion of B cells.
Narendra Choudhary, Anupama Borker
openaire +3 more sources
Rituximab monitoring and redosing in pediatric neuromyelitis optica spectrum disorder. [PDF]
, 2016 OBJECTIVE: To study rituximab in pediatric neuromyelitis optica (NMO)/NMO spectrum disorders (NMOSD) and the relationship between rituximab, B cell repopulation, and relapses in order to improve rituximab monitoring and redosing.
Alper, G +14 more
core +1 more source
Course of neuromyelitis optica during inadvertent pregnancy in a patient treated with rituximab [PDF]
, 2009 In neuromyelitis optica (NMO), the monoclonal B-cell antibody rituximab is a therapeutic option. Little is known about the course of NMO and the safety of rituximab during pregnancy.
Hohlfeld, R. +4 more
core +1 more source
Use of Rituximab in autoimmune hemolytic anemia associated with non-hodgkin lymphomas [PDF]
, 2011 The association between non-Hodgkin lymphomas and autoimmune disorders is a well-known event. Also autoimmune hemolytic anemia (AHA), although much more frequent in patients with chronic lymphocytic leukemia (CLL), has been described in this group of ...
Fozza, Claudio +1 more
core +4 more sources
Metabolomic profiling predicts outcome of rituximab therapy in rheumatoid arthritis. [PDF]
, 2016 ObjectiveTo determine whether characterisation of patients' metabolic profiles, utilising nuclear magnetic resonance (NMR) and mass spectrometry (MS), could predict response to rituximab therapy. 23 patients with active, seropositive rheumatoid arthritis
Boyle, David +6 more
core +2 more sources